Cytoreductive surgery for recurrent ovarian cancer

被引:9
作者
Hauspy, Jan [1 ]
Covens, Allan [1 ]
机构
[1] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Toronto, ON, Canada
关键词
cytoreductive surgery; recurrent ovarian cancer;
D O I
10.1097/GCO.0b013e3280115f40
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Purpose of review The issue facing clinicians managing ovarian cancer has evolved over the past three decades from treatment for cure and subsequently palliation to prolongation of survival for most patients. The purpose of this paper is to review the data, rationale, and issues surrounding cytoreductive surgery in recurrent ovarian cancer and its potential role in this new paradigm shift. Recent findings Abundant retrospective series report prolongation of survival with secondary cytoreductive surgery in recurrent ovarian cancer. Selection bias, publication bias, and subsequent therapies, however are confouding factors for survival. As management of ovarian cancer has recently evolved to a treatment of a 'chronic disease', surgery (which has a definite role in primary therapy) should be considered. Summary No prospective randomized studies have been performed to date, and therefore adoption of this method of management has been limited. The absence of good data leaves clinicians without clear direction on how to best manage patients. Patients with favorable characteristics such as a long disease free interval, good performance status, a single or few small intra-abdominal recurrences may benefit from secondary cytoreduction. A prospective randomized study is needed.
引用
收藏
页码:15 / 21
页数:7
相关论文
共 50 条
[1]   Ovarian cancer surgical resectability: Relative impact of disease, patient status, and surgeon [J].
Aletti, GD ;
Gostout, BS ;
Podratz, KC ;
Cliby, WA .
GYNECOLOGIC ONCOLOGY, 2006, 100 (01) :33-37
[2]   Intraperitoneal cisplatin and paclitaxel in ovarian cancer [J].
Armstrong, DK ;
Bundy, B ;
Wenzel, L ;
Huang, HQ ;
Baergen, R ;
Lele, S ;
Copeland, LJ ;
Walker, JL ;
Burger, RA .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) :34-43
[3]   The role of secondary cytoreduction in the treatment of ovarian cancer: Hacettepe University experience [J].
Ayhan, A ;
Gultekin, M ;
Taskiran, C ;
Aksan, G ;
Celik, NY ;
Dursun, P ;
Salman, MC ;
Yuce, K ;
Kucukali, T .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2006, 194 (01) :49-56
[4]  
BEREK JS, 1983, OBSTET GYNECOL, V61, P189
[5]   Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT [J].
Bristow, RE ;
del Carmen, MG ;
Pannu, HK ;
Cohade, C ;
Zahurak, ML ;
Fishman, EK ;
Wahl, RL ;
Montz, FJ .
GYNECOLOGIC ONCOLOGY, 2003, 90 (03) :519-528
[6]   Surgical treatment of recurrent ovarian cancer: report of 21 cases and a review of the literature [J].
Cormio, G ;
di Vagno, G ;
Cazzolla, A ;
Bettocchi, S ;
di Gesu', G ;
Loverro, G ;
Selvaggi, L .
EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 1999, 86 (02) :185-188
[7]   A RANDOMIZED TRIAL OF CYCLOPHOSPHAMIDE, DOXORUBICIN, AND CISPLATIN WITH OR WITHOUT BACILLUS CALMETTE-GUERIN IN PATIENTS WITH SUBOPTIMAL STAGE-III AND STAGE-IV OVARIAN-CANCER - A GYNECOLOGIC ONCOLOGY GROUP-STUDY [J].
CREASMAN, WT ;
OMURA, GA ;
BRADY, MF ;
YORDAN, E ;
DISAIA, PJ ;
BEECHAM, J .
GYNECOLOGIC ONCOLOGY, 1990, 39 (03) :239-243
[8]   A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8) [J].
du Bois, A ;
Belau, A ;
Wagner, U ;
Pfisterer, J ;
Schmalfeldt, B ;
Richter, B ;
Staehle, A ;
Jackisch, C ;
Lueck, HJ ;
Schroeder, W ;
Burges, A ;
Olbricht, S ;
Elser, G .
GYNECOLOGIC ONCOLOGY, 2005, 96 (02) :444-451
[9]  
Eisenkop SM, 2000, CANCER, V88, P144, DOI 10.1002/(SICI)1097-0142(20000101)88:1<144::AID-CNCR20>3.0.CO
[10]  
2-X